8-K current report · filed Oct 23, 2026

Aardvark Therapeutics, Inc. (AARD) 8-K Current Report: October 23, 2026

Item 8.01Item EX-99.1Item EX-99.2AARD overview

Short answer

Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Exploratory efficacy data released from terminated Phase 3 HERO and OLE trials.

Aardvark Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Exploratory efficacy data released from terminated Phase 3 HERO and OLE trials
  • Investor webinar held October 23, 2026 at 8:00 a.m. ET
  • Results and presentation available in Exhibits 99.1 and 99.2, requiring review for efficacy details
  • Terminated Phase 3 program limits immediate clinical and commercial relevance

Item EX-99.1 · Exhibit EX-99.1

  • HERO trial stopped early with 67 of 90 planned participants, making all efficacy results exploratory
  • OLE participants switching from placebo to ARD-101 showed average HQ-CT reduction of 6 points by Day 28
  • ARD-101 generally well tolerated, but one cardiac serious adverse event involved 800 mg BID and pitolisant interaction
  • FDA lifted ARD-101’s full clinical hold, enabling plans for a lower-dose Phase 3 program
  • Company expects to resume PWS clinical activities in 2027, pending FDA alignment on trial design

Item EX-99.2 · Exhibit EX-99.2

  • FDA clinical hold lifted in October 2026, allowing Aardvark to resume ARD-101 development for Prader-Willi syndrome
  • HERO enrollment truncated at 67 participants versus planned 90, making efficacy results exploratory rather than confirmatory
  • ARD-101 showed modestly greater hyperphagia improvement through Week 8, with benefits reversing after treatment stopped
  • Safety generally favorable, but one Grade 4 polymorphic ventricular tachycardia event occurred at 800 mg BID with pitolisant
  • Therapeutic-dose ECG studies found no QRS prolongation at 200 mg BID (n=45) or 400 mg BID (n=42)

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aardvark Therapeutics, Inc. 8-K filings

Get the next AARD 8-K as it lands

Follow AARD for push alerts, or ask the research agent what this filing means.